CRIS Current Research Information System

Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) have shown significant cardiovascular benefits in patients with and without type 2 diabetes mellitus (T2DM). They have also gained interest for their potential anti-arrhythmic role and their ability to reduce the occurrence of atrial fibrillation (AF) and ventricular arrhythmias (VAs) in T2DM and heart failure patients.

In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study / Cesaro, Arturo; Gragnano, Felice; Paolisso, Pasquale; Bergamaschi, Luca; Gallinoro, Emanuele; Sardu, Celestino; Mileva, Niya; Foa, Alberto; Armillotta, Matteo; Sansonetti, Angelo; Amicone, Sara; Impellizzeri, Andrea; Esposito, Giuseppe; Morici, Nuccia; Oreglia, Jacopo Andrea; Casella, Gianni; Mauro, Ciro; Vassilev, Dobrin; Galie, Nazzareno; Santulli, Gaetano; Pizzi, Carmine; Barbato, Emanuele; Calabrò, Paolo; Marfella, Raffaele. - In: FRONTIERS IN CARDIOVASCULAR MEDICINE. - ISSN 2297-055X. - ELETTRONICO. - 9:(2022), pp. 1-9. [10.3389/fcvm.2022.1012220]

In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study

Paolisso, Pasquale;Bergamaschi, Luca;Foa, Alberto;Armillotta, Matteo;Sansonetti, Angelo;Amicone, Sara;Impellizzeri, Andrea;Galie, Nazzareno;Pizzi, Carmine;
2022

Abstract

Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) have shown significant cardiovascular benefits in patients with and without type 2 diabetes mellitus (T2DM). They have also gained interest for their potential anti-arrhythmic role and their ability to reduce the occurrence of atrial fibrillation (AF) and ventricular arrhythmias (VAs) in T2DM and heart failure patients.
2022
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study / Cesaro, Arturo; Gragnano, Felice; Paolisso, Pasquale; Bergamaschi, Luca; Gallinoro, Emanuele; Sardu, Celestino; Mileva, Niya; Foa, Alberto; Armillotta, Matteo; Sansonetti, Angelo; Amicone, Sara; Impellizzeri, Andrea; Esposito, Giuseppe; Morici, Nuccia; Oreglia, Jacopo Andrea; Casella, Gianni; Mauro, Ciro; Vassilev, Dobrin; Galie, Nazzareno; Santulli, Gaetano; Pizzi, Carmine; Barbato, Emanuele; Calabrò, Paolo; Marfella, Raffaele. - In: FRONTIERS IN CARDIOVASCULAR MEDICINE. - ISSN 2297-055X. - ELETTRONICO. - 9:(2022), pp. 1-9. [10.3389/fcvm.2022.1012220]
Cesaro, Arturo; Gragnano, Felice; Paolisso, Pasquale; Bergamaschi, Luca; Gallinoro, Emanuele; Sardu, Celestino; Mileva, Niya; Foa, Alberto; Armillotta, Matteo; Sansonetti, Angelo; Amicone, Sara; Impellizzeri, Andrea; Esposito, Giuseppe; Morici, Nuccia; Oreglia, Jacopo Andrea; Casella, Gianni; Mauro, Ciro; Vassilev, Dobrin; Galie, Nazzareno; Santulli, Gaetano; Pizzi, Carmine; Barbato, Emanuele; Calabrò, Paolo; Marfella, Raffaele
1.01 Articolo in rivista
File in questo prodotto:
File Dimensione Formato  
fcvm-09-1012220.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.04 MB
Formato Adobe PDF
Visualizza/Apri
1.04 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/910720
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 26
social impact